# Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

> **NCT04138485** · PHASE2 · WITHDRAWN · sponsor: **CSL Behring**

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **BIOLOGICAL:** IgPro10
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04138485
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-20
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-09-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to business reasons, not safety issues
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138485, "Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04138485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*